tirzepatide creatinine reduces albuminuria among adults with type 2 diabetes in SURPASS trials Interplay of Chronic Kidney Disease

Just over a week before the PDUFA action date, Axogen announced FDA had extended the target goal date 3-months due to submission of a Major Amendment in response to an information request

Dagan, Y., Zisapel, N., Nof, D., Laudon, M., & Atsmon, J

10.3390/ijms21197152 42 LeeO

The conversation around GLP-1 medications has exploded, and with it, a growing mix of hype, fear, and misinformation that is pushing some patients and clinics toward unapproved, higher-risk options

Substantial reductions in ASCVD events and death are seen when multiple ASCVD risk factors are addressed simultaneously, with long-standing benefits [8, 9]

At the lysosomal membrane, SLC7A11 mediates proton leak, preventing hyperacidity through cystine efflux and Glu influx of lysosomes 140